Register for our free email digests:
Array BioPharma Inc.
Division of Pfizer Inc.
www.arraybiopharma.com
Latest From Array BioPharma Inc.
ASLAN Falls As TreeTopp BTC Study Fails
ASLAN’s pivotal Phase II TreeTopp study of varlitinib in biliary tract cancer missed its co-primary endpoints of progression-free survival and overall response rate.
Keeping Track: Industry Beefs Up 2020 Review Pipeline With Submissions Galore
The latest drug development news and highlights from our US FDA Performance Tracker.
Brighter News For Varlitinib As Results In Tough Cancer Type Encourage ASLAN
Following a major setback in another indication earlier this year, ASLAN’s lead asset is now seen as a potential new option for second-line use in biliary tract cancer following promising new data from a Chinese trial.
Celgene's Otezla Sale Shows FTC Wants Merging Companies To Ditch Marketed, Not Pipeline, Products
Companies used to be able to pick which overlapping products to divest to get US Federal Trade Commission merger approval but an FTC study showed certain divestitures weren't working.
Company Information
- Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Cardiovascular
- Infectious & Viral Diseases
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
-
Ron Squarer, CEO
Jason Haddock, CFO
Andrew Robbins, COO
Nicholas A Saccomano, PhD, CSO
Victor Sandor, MD, CMO - Contact Info
-
Array BioPharma Inc.
Phone: (303) 381-6600
3200 Walnut St.
Boulder, CO 80301
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice